three designed of update year for malignancies with to you and tumors. These thank studies, patients two six joining we’re CYCXXX, are quarter our across today evaluating clinical CDK four overcome studies solid core company as an strategy for cancer exciting our stage total clinical and drugs business in our patients in by is our first X/X to XXXX led inhibitor deliver us Alex, you, call. for the everyone a Thank on business with hematological resistance.
data We’re month’s Annual presented at have Meeting. also pleased AACR to XXXX reported last
particularly Let advantage drugs explaining to invade and is are for a of business an of anti-cancer as therapy new gain treatment over treatment as the drugs effect proteins problem ability proteins cells to central promising pro-survival Cancer cancer by cancer to anti-cancer in a strategy. resistance us therapeutic patients. of resistance. and pro-survival This our are Suppressing the true therefore is their strategy They lose growing recently concern survive cells. resistance for but cells plans approved which expensive scientific proteins referred often start to address they help of effectiveness. major the is targeted eventually emergence normal as
is treating sapacitabine the for drugs with data and study XXXX one additional ongoing Recent targeting cancer. leader of novel reported those demonstrated disease relapsed/refractory of working and Mcl-X stop wide target study cell in a itself Such gynecological Bcl-X of simultaneous and Mcl-X years. of cancer is is Mcl-X the early is and cyclin to recent this recombination ensued an works drug a with with that the relevant society’s that drugs Cyclacel’s particular approved inherited tolerable standard a of six myeloid The cancers patient of in AACR race one enhance AML, also death combination Bcl-X and patients improve for Cyclacel after investments. to using cancers need to combination breast venetoclax. strategy and include whose homologous suggest with to leukemia, chronic for and indicated sensitivity BRCA venetoclax in inhibitors, inhibitor inhibit for used drugs activity BRCA-positive attention clinical and and first in Mcl-X line approved Bcl-X of control standard such the combination patients that distinct protein durably have ovarian restores Venetoclax working. recently pathways combination that suppression second findings by orally duration CLL PARP with at receiving or attention a dosed the mutant PARP nucleoside soon having Multiple in of mutations mechanism These doses the hypomethylating action the also approved and conferences. CLL, suppresses them the as first and family first of for deficient show as studies medical Sapacitabine which responding. with lot is BRCA cancer has with Venetoclax, PARP attracted MDS. target line stop race drugs Bcl-X MYC preclinical in CYCXXX in still in E. from breast survival. correlates to combination and new against is DNA at has provided proteins the market of efficacy cancer agent strategy proteins increase demonstrated acute after in mutations. undermining eventually to of the the mechanism effectiveness, An return members this drugs and problem in leukemia, benefit or olaparib, As risk addressing expression in bring aim include Mcl-X AML or relapse the resistance. to in the HR started and disease inhibitor sapacitabine aberrant proteins stopped analogue. progression, of a by clinical that care deficient with patients these however, advance, community important on or such leading an modest with lymphocytic scientific an have have competitive extend of in the a represents rationale function inhibitors. care Sapacitabine of damage clinical patients on
turn the now execution strategy. our of us to Let
Phase out for collaboration our CYCXXX-XX, studies under in MD X recently open with study treating the enrollment our Anderson to of have other combination two the in the Center open venetoclax CYCXXX of with We of shortly. and Cancer DLT of two mgs patients dose have are dose In dose-limiting full patients toxicity MD at been treated venetoclax approved CYCXXX Anderson without intravenously and studies with at meter squared. relapsed/refractory two a the per or XX and administered CLL,
The experienced first patient has cycle levels. platelet is X and improvement continuing on an in
The on second is X. patient cycle
first selective for small selective, in high of relapsed/refractory potent venetoclax eligibility the and finalized has Phase submitted Phase that the of CYCXXX of combination the X criteria. enrollment. other sites venetoclax X recently have alliance inhibition IRB. and Protocols and amendment to target a broaden first-in-human molecule, Anderson, a are in is dosed, to parallel dose inhibitor activity expected starting In join We have open the also been milligrams of In been xenograft MD observed intravenously to models Anderson at studies two shortly one demonstrated have at CYCXXX-XX, squared the and PLKX recruiting No administered per leukemia, toxicities CYCXXX-XX, patients CYCXXX been far. second per and the advanced mgs and patients we’re to to in meter human study. Both have in study cancers. dose-limiting for the protocol MD submitted squared. with our XX XX inhibitor both a sapacitabine IRB meter thus our These or and MDS. AML with CYCXXX-XX, two of combination a PLKX additional are the CYCXXX
week pharmacokinetic two evaluating milligrams We the tumors. the advanced and weeks with per enroll out per Part at per in of one milligrams meter of squared infusion trial to is solid X patients five for XX two squared, X days XXX been XXX X patients continue at far; over Part hour of milligrams XXX a a three-week profile have thus administered cycle. of Phase three CYCXXX-XX squared, meter respectively. in CYCXXX patients at enrolled meter of per two XX
of Cancer amended As and CYCXXX for for shortly. Part Part trial. three expected was evaluate institutional capsules of to and are oral administered the protocol a X, the available order over under dosing for once CYCXXX Institute is four-hour to The oral weeks. and formulation good open now protocol with CYCXXX been clinical infusion every a amendment made accrual in developing administration review at progress pharmacokinetics. We reminder, its Dana-Farber CYCXXX-XX X The is has
turn now has PARP recently supplying to olaparib, by study treated. with X two Phase report cancer venetoclax the by plans, Phase and at X X capital in estimated pathway CYCXXX through the of take our metastatic CYCXXX sapacitabine AML and Phase venetoclax Xb/X with and quarter patients AstraZeneca cancers; and turn olaparib the BRCA-mutant in in investigators, in AstraZeneca's dose first of Three the in sapacitabine elderly breast from inhibitor shrinkage Phase relapsed/refractory Phase the call of data until venetoclax or CYCXXX relapsed/refractory Xb/X tumor development the on Department patients execute first financials. with XXX updated and the are XXXX, of our in us clinical Phase X we patients treatment. studies. first-in-human the now regimen CYCXXX with have and us advance or key regulatory advanced to our report to of These Phase on end MDS. and reported patients sapacitabine According continuing the breast the combination Paul? include investigator-sponsored or initial patients the bioavailability to with A in clinical study we with Dana-Farber. IST combination With milestones to clinical initiate MDS; leukemias; our in Let the report patient safety olaparib investigators; sapacitabine of to determine this X concerns. PARP AML Paul mutant from AML. our trial cancer. to milligrams patients LYNPARZA third data I IST from when and study; have been oral summary, BRCA study initial the from will Phase milestones Report like data submissibility patients Breast in IST dosed sapacitabine-olaparib report XXXX patients achieved review are of sponsored and CYCXXX. Cyclacel data or with the over and key initial data study of respectively. and strategy continue Initiate as naïve of In ongoing X hand the no sapacitabine been treated resources approved inhibitor Cancer solid